Remoxipride
未知生产厂商
Remoxipride is an discontinued atypical antipsychotic selective for dopamine D2 receptors.
Remoxipride is an discontinued atypical antipsychotic selective for dopamine D2 receptors.
Remoxipride is an atypical antipsychotic dopamine D antagonist. Chronic use upregulates the expression of D receptors, while downregulating the expression of D and D receptors in the prefrontal cortex. This activity may be related to the antipsychotic activity of remoxipride. Remoxipride displays weaker binding to D dopaminergic receptors that dopamine. This weaker binding is thought to account for the reduced incidence of Parkinsonism. Remoxipride also increases expression of the protein Fos in the nucleus accumbens but not the dorsolateral striatum, which may be responsible for a reduced incidence of extrapyramidal symptoms.
用于治疗急性和慢性精神分裂症和以妄想、幻觉和思维紊乱为主要症状的其他精神病。
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
